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A PHlaxidophenacyl ester of PGE, (Pl-Ijaxido-PG%) was synthesized and used to photoaffinity label the protein component of the high affinity 
PGE, binding site in cardiac sarcolemma membrane. Photolysis of the isolated cardiac sarcolemmal vesicles in the presence of IWjaxido-PGE, 
resulted in the covalent labelling of a protein component that migrated on sodium dodecyl sulfate-polyacrylamide g ls with an apparent molecular 
weight of 100000. Incorporation of the I%jaxido-PGE, did not occur in the absence of photolysis. The photolabelling of the IOO-kDa protein 
by PH]axido-PGE, was inhibited by excess unlabelled PGE, and axido-PG&. Specific binding of PHlazido-PGE, was displaced by excess unlabelled 
PGE, or azido-PG&, but not PGF,,, Cketo-PGF,. or PGDZ. These. results indicate that the IOO-kDa photoalEnity labelled PH]azido-PGE, binding 
protein contains the binding site for PGE, in isolated cardiac sarcolemma membranes. 
Prostaglandin receptor; Cardiac sarcolemma; Photolabelling 
1. INTRODUCTION 
While prostaglandin Ez (PGE2) produces a broad 
range of biological responses [l-4], the exact 
mechanism of its actions remain unclear. The initiating 
process is believed to be the recognition of PGE2 by a 
specific cellular receptor. High affinity [3H]PGEz bind- 
ing sites have been extensively characterized in a variety 
of homogenates and isolated cells derived from tissues 
that are known targets for PGEz action [2]. In cardiac 
muscle direct action of PGE2 involves alterations of 
glucose oxidation, myocardial 02 consumption, 
myocardial triglyceride, and CAMP levels, and SL 
Na + /K + -dependent ATPase activity [3-81. We have 
recently demonstrated that bovine heart SL vesicles 
contain high affinity stereo-specific binding sites for 
PGE2, which are functionally coupled to adenylate 
cyclase [8]. The receptor concentration is relatively high 
(- 1 pmol/mg protein) in cardiac SL vesicles, and bind- 
ing is specific, since PGE2 and PGEi bind to the recep- 
tor while other prostaglandins fail to bind [8]. SL 
vesicles may therefore be considered an excellent mem- 
brane source in which to identify and purify the PGEz 
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receptor. Despite considerable interest in the function 
of prostaglandins, few attempts have been made to 
identify the membrane receptor [g-14]. Full delineation 
of both the properties of PGE2 binding and the iden- 
tification and subsequent isolation of the PGEz binding 
protein seems essential if the molecular basis of PGE2 
action in the heart and other tissues is to be understood. 
We report here the synthesis of an azidophenacyl 
ester of PGE2 (azido-PGEz), which was used as a 
specific probe for the identification of the PGEz recep- 
tor in cardiac SL. Our results show that azido-PGE2 is 
an excellent photoaffinity ligand. Direct photolabelling 
of isolated cardiac SL with [3H]azido-PGE2 has allowed 
us to identify a lOO-kDa [3H]azido-PGEz binding 
polypeptide. 
2. EXPERIMENTAL 
SL vesicles were isolated from bovine heart (left ventricle only) ac- 
cording to the procedures of Jones [15]. Vesicles were suspended in 
3-5 mg/ml in 100 mM NaCl and 20 mM Hepes, pH 7.4, frozen in li- 
quid NZ and stored at -85°C. Protein concentration was determined 
by the method of Lowry et al. [16]. 
Unlabelled and [“Hlazido-PGEz were synthesized as follows. 
Unlabelled PGEz (3.4 mg, 0.0097 mmol) in acetone (1 ml), was mixed 
with potassium carbonate (4 mg, 0.029 mmol), and heated at 40°C 
under an atmosphere of argon for 40 min. The resulting mixture was 
stirred with p-azidophenacyl bromide (ICN Biochemicals, Cleveland, 
OH) (2.5 mg, 0.01 mmol) at 40°C for 60 min. The mixture was subse- 
quently cooIed to room temperature, acidified with aqueous 1 N HCl, 
and extracted with methylene chloride. Extracts were dried (MgSO.,), 
filtered and concentrated. The residue was purified by flash 
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chromatography on sihca gel eluting with a solution of 
chloroform:ethyt acetate:methanol(6:5: I) containing a small amount 
of acetic acid (3 drops/l2 ml) and water (1 drop/l2 ml) to give p- 
azidopbenacyl ester of PGEz (a&do-PGEz): ir (CH2C4 cast) 3374 
(OH), 2126 (Ns), 1744 (C=O), 1701 (C=O), and 1598 (~ornatjc~ 
cm- ‘; ‘H NMR (CDClp) 6 7.92, 7.11 (both d, 2H each, J = 9 Hz 
each, aromatic), 5.72 (dd, IH, J = 15, J’ = 6 Hz, -CH =), 5.60 (dd, 
lH,J = 15,J’ = 8Hz,-CH-),54O(m,ZH,2 x -CH=),5.31,5.30 
(both s, 2H each, -OCHz- and 2 x -OH), 4.11 (m, 2H, 2 X-CHOW), 
and 0.89 &3H, 3 = 7 Hz, -CHs). The same method was applied for 
the synthesis of ~-~dophenacy~ ester of ]5,6,8, f I, 12, 14, 15 - ‘H 
(N)]PGl%. The fractions obtained from sihca gei (0.7 ml) were 
monitored by liquid scintillation counting. Radioactive fractious were 
combined, concentrated In a Speed-Vat Cancentrator (Sevant Kn- 
struments), dissolved in dimethylsulfoxide and used for photolysis ex- 
periments. 
Competition of [3H]PGE~ and [‘H]azido-PGEa binding was carried 
out as described by Lopaschuk et al. f8]. For photo&&s, the SL 
vesicles were incubated with 18 r&i fsH]azido-PGEz in the presence or 
absence of uniabelled PG& or azido-PGEZ, in a buffer containing 
100 mM NaCl, 0.1 mM EGTA, and 20 mM Hepes, pH 7.4 at 37YJ 
for 60 min. The binding reaction was carried out in the dark to pre- 
vent any undesired reactions from laboratory hght when azido-PGEz 
was used. All photolysis experiments were done in an RPR 208 
preparative reactor (Rayonet, The Southern New England Ultraviolet 
Co., Midd~etown~ CM) equipped with RPR 3500-A !amps. With the 
reactor at 4°C (cold room), the air temperature surrounding the sam- 
ple was maintained at 4’C by an electric fan. In order to prevent he 
possible destruction of sensitive sulfur or aromatic amino acid in pro- 
teins during the photolysis, cross-linking was carried out for 10 min 
using an irradiation source at 350 nm light [ 161. SDS-PAGE was per- 
formed using 5-15% acrylamide gradient gels according to the pro- 
cedure of Laemmli fll]. Gels were stained with Coomassie Blue, and 
destained in a solution of 10% acetic acid and 5% methanol. 
[‘Hjazido-PGEz incorporation was detected by fluorography and/or 
liquid scintillation counting of gel slices. Gel slices (2 mm) were in- 
cubated OVernight at 37% ha 0.2 ml of Protoso] before liquid scintilht- 
tion fluid was added. Gels used for fluorography were treated with 
Amplify before drying and then exposed at -85°C using Kodak 
XAR-5 fRm. Molecular weight standards used with size in parentheses 
were: myosin (200 kDa); @-galactosidase (116 kDa); phosphorylase b
(97 kDa); bovine serum albumin (66 kDa); ovalbumin (42 kDa). 
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Fig. 1. Structure of azido-PG& (a~dopb~nacyl ester of PGEz). 
Azido-PGEz (1) and f3H]azido-PG& (2) were synthesized as describ- 
ed under Experimenta!. T denotes positions of f3H]. 
PPQ5 
Fig.2 Competition of f’H]PGEz binding to cardiac SL vesicles by 
unfabeIIed PGEl and a&do-PGEt. Competition of i3H]PGEt binding 
was carried out in the presence of varying concentrations of unlabel- 
Ied PGEz or azido-PGEz as described under Experimental. 100% 
represents total binding to the SL vesicles at 2 nM [‘H]PGEz (1.2 
pmol/mg protein). Average values + SE of three experiments are 
presented. 
3, RESUZTS AlYLt DISCUSSION 
Fig. 1 shows the chemical structure of the azido- 
PGEz used in this study. To compare the properties of 
the azido-PGEz with those of PGE2, we examined the 
effect of azido-PGEt on specific binding of 13H]PGEz 
to the SL vesicles. [%I]PGEt binding was inhibited by 
unlabelled PGEz with an ICSO value of approximately 5 
x 1o-9 M (Fig. 2). Azido-PGEz competed with 
[3H]PGEz binding to SC vesicles although it was a less 
effective inhibitor of this binding than unlabelled 
PGEt. The I& value for azido-PGEz was approx- 
imately 4 x 10 -? M (Fig. 2). Differences between the 
chemical structure of PGE2 and azido-PGE2 likely ac- 
count for the reduced ability of azido-PGE2 to compete 
for 13HJPGEz bound to SL. This conclusion is sup- 
ported by the relative ability of other PGs to displace 
[3H]PGE~ from SL vesicles fg]. In cardiac SL vesicles 
f3H]PGE2 binding is significantly inhibited by unlabel- 
led PGEt, but only weakly by PGFz~, 6-keto-PGFI,, 
and PGDz [8]. The inability of PGFza to compete with 
Table I 
Effects of different prostagiandins on a&do-PGEz binding to cardiac 
SL vesicles 
Prostaglandins [3H]azido-PGEz binding 
(pmol/mg protein) (ala of control) 
none 0.50 (loo) 
PGEz 0.14 (28) 
azido-PGEZ 0.08 (16) 
PGFza 0.46 (92) 
6-keto-PGFr, 0.46 (92) 
PGDz 0.45 (90) 
(‘Hlazido-PGEZ binding was carried out in the presence of 500 CM 
concentrations of unlabehed PGEz, azido-PGEz, PGFz,, 6-keto- 
PGFr,, and PGDz, as described under Experimental. 
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f3H]PGE2 binding sites in SL vesicles [8] is a good ex- 
ample of how a small change in chemical structure 
(substitution of the keto group at carbon-9 in PGE2 
with a hydroxyl group) significantly alters binding ac- 
tivity. In contrast, substitution of the COOH results in 
relatively much smaller change in affinity, probably due 
to steric hindrance, rather than an alteration in the bin- 
ding site of PGEt. 
In order to characterize the specificity of the binding 
of azido-PGE2 to SL the effects of PGFzII, 6-keto- 
PGFr,, and PGDz on [3H]azido-PGE2 binding to the 
membrane was studied. Table I shows that both 
unlabelled PGEz and azido-PGEz produced significant 
inhibition of [3H]azido-PGEz binding to the mem- 
brane. PGFza, 6-keto-PGFi,, and PGDz failed to 
displace more than 10% of [3H]azido-PGEz from SL 
vesicles (Table I). These results show that [3H]azido- 
PGEz binding to SL occurred at a membrane protein 
that also binds PGE2. 
Fig. 3 shows the ~3H]~ido-PGE2 labelling profile ob- 
tained for the cardiac SL vesicles following photolysis. 
A major peak of [3H]azido-PGEz incorporation was 
observed into a lOO-kDa protein band, along with a 
broad peak of [3H]azido-PGEZ incorporation at the dye 
front (Fig. 3). This broad peak probably represents 
either free [3H)azido-PGEz or nonspecific incorpora- 
tion of 13H]azido-PGEz into membrane phospholipids. 
When aliquots of the same membranes were photolysed 
in the presence of unlabelled PGEz (lo- 3 M) (Fig. 3B) 
or azido-PGEz (low3 M) (Fig. 3C) the amount of 
covalently bound f3H]azido-PGEz in the lOO-kDa pro- 
tein was decreased by approximately 70%. In the 
absence of photolysis, no incorporation of [3H]azido- 
PGE2 was observed (Fig. 3A). If excess unlabelled 
PGE2 was added after photolysis, as opposed to being 
present during photolysis, no alteration in the amount 
of [3H]azido-PGEz found in the lOO-kDa protein band 
was seen (data not shown). Based on the displacement 
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Fig.3. Photoaffinity labelling of cardiac SL membrane with 
[3H]azido-PGEz. Cardiac SL vesicles were photolabelled with 
[“Hlazido-PGEZ in the absence or presence of unlabelled PGEz (lo- 3 
M) (B) or azido-PGEt (10 - 3 M) (C) as described under Experimental. 
(A) no photolysis. Samples (30 pg of protein) were subjected to SDS- 
PAGE. Following staining and destaining, gel lanes were sliced in 2 
mm sections and [‘Hlazido-PGEz incorporation was measured by li- 
quid scintillation counting. Arrows depict the location of molecular 
weight standards and tracking dye (TD). Numbers represent M, x 10’. 
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Fig.4. Photolabelling of cardiac sarcolemma membranes with 
[‘Hlazido-POE*. Cardiac sarcolemmal vesicles (1 mg of protein/ml) 
were photolabelled with (‘Hlazido-PGEz in the absence or presence of 
unlabelled PGEz (10 - 3 M) as described under Experimental. Samples 
(30 pg of protein). FoIlowing staining and destaining, the slab gel was 
then treated with Amplify and exposed to X-ray film. Lanes 1 and 2 
are Coomassie blue stained molecular weight standards and proteins 
of cardiac sarcolemmal vesicles, respectively. Numbers represent 
M,x 103. 
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of labelled azido-PGEz in Fig. 3C we determined that 
photolabelling of the lOO-kDa protein in SL membranes 
with [3H]azido-PGEt was more than 70% specific. This 
is in agreement with photolabelling of @-adrenergic 
receptor molecules [l&19]. The autoradiogram of 
[3H]azido-PGE2 incorporation obtained for the same 
labelled membranes as used in Fig. 3 is shown in Fig. 4. 
[‘H]azido-PGEz was predominantly incorporated into 
one protein band of molecular weight of about 100 000 
(Fig. 4, lane 3). Addition of unlabelled PGEz (lo- 3 M) 
to the incubation buffer before photolysis greatly 
reduces the incorporation of [3H]azido-PGEz into the 
100,000 dalton protein band (Fig. 4, lane 4). 
The data presented here are the first direct identifica- 
tion of the PGEz binding protein (receptor) using a 
photoaf~nity derivative of PGEz. The results of our ex- 
periments demonstrate that [3H]azido-PGEz is an ex- 
cellent photoaffinity ligand for the high-affinity PGEp 
binding sites in isolated cardiac SL membranes, and 
therefore should be useful in identifying PGEz recep- 
tors in other tissues. Using 13H]~ido”PGE2, we show 
that a lOO-kDa polypeptide is specifically labelled by 
this compound in cardiac SL membranes. We believe 
that this lOO-kDa protein band corresponds to the 
PGEz receptor in the heart. The molecular weight of the 
cardiac PGEt receptor assessed by the direct 
photolabel~ng method in this study resembles the 
values obtained in other tissues by indirect methods 
[9- 121. PGE2 binding protein in rat liver plasma mem- 
brane [9], murine macrophage-like cells [lo], bovine 
adrenal medulla [l 1) and canine renal outer medulla 
[ 121 was postulated to be a protein of molecular weight 
between 65 000 and 110 000. We have recently isolated 
the lOO-kDa protein from bovine heart SL membranes 
and showed that it specifically binds both [3H]PGEz 
and [3H]azido-PGEz (unpublished observations). 
In summary, we have identified a lOO-kDa protein 
from cardiac SL which binds specifically [3H]azido- 
PGE2. The specificity of ]3H]azido-PGEz provides an 
excellent tool for the identification and isolation of 
PGEz receptor in the heart and other tissues. 
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